Beam Therapeutics
BEAM
194 hedge funds and large institutions have $2.05B invested in Beam Therapeutics in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 31 closing their positions.
134% more call options, than puts
Call options by funds: $16M | Put options by funds: $6.86M
66% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 47
11% more capital invested
Capital invested by funds: $1.85B → $2.05B (+$201M)
0.84% more ownership
Funds ownership: 83.39% → 84.24% (+0.84%)
6% less funds holding
Funds holding: 206 → 194 (-12)
35% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 31
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
BlackRock
New York
|
+$34.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$18.1M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$18.1M |
Top Sellers
BEAM Hedge Fund Activity: Q2 2023 in Review
194 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2023, worth a combined $2.05B — up 11% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of BEAM and 20 opened new positions — a net loss of 11 holders — while 47 trimmed existing stakes and 78 added.
The largest buyer was BlackRock, adding an estimated $34.4M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $15.1M sold.
- 194 institutional investors held Beam Therapeutics (BEAM) as of Q2 2023, down from 206 in Q1 2023.
- Funds reported $2.05B of Beam Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
- 20 funds opened new Beam Therapeutics positions in Q2 2023 and 31 closed out, a net change of -11 holders.
- The largest Beam Therapeutics buyer in Q2 2023 was BlackRock, an estimated $34.4M added.
- The largest Beam Therapeutics seller in Q2 2023 was Capital Research Global Investors, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2023.